Om

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical holding company focused on oncology and onco-dermatology therapies. Through its Israeli subsidiary, the group is engaged in the discovery and development of novel anticancer medicines targeting cancer metabolism and related pathways in solid tumors and skin cancers. Its research and development activities concentrate on first-in-class small-molecule drug candidates intended for oncologic indications and dermatologic conditions such as actinic keratosis and cutaneous T-cell lymphoma. Vidac Pharma Holding PLC primarily operates in the biotechnology segment of the broader pharmaceuticals and healthcare sector, serving the needs of clinicians and patients seeking targeted, mechanism-based treatments. Incorporated in 2021 and headquartered in London, United Kingdom, the company functions as an investment holding entity while its operating subsidiary conducts the core scientific, preclinical, and clinical work. Vidac Pharma Holding PLC occupies a niche position in the market by focusing on metabolism-based cancer therapies and onco-dermatology, contributing to innovation in specialized therapeutic areas where treatment options remain limited.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VIDAC PHARMA HOLDING MED ENDAVU: Køb Vidac Pharma Holding ($T9G) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Vidac Pharma Holding, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.